Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-04937319

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Glucokinase activators (GKAs) are newly drug class proposed for diabetes treatment. This systematic review aimed to assess the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 3
  • table 4
2019
2019
Abstract A Css-MRTpo superposition method was devised to predict (retrospectively) oral plasma concentration–time profiles of PF… Expand
2017
2017
Abstract 1. The partial glucokinase activator N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy… Expand
2017
2017
Glucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2016
2016
Glucokinase enhances glucose conversion to glucose‐6‐phosphate, causing glucose‐stimulated insulin secretion from pancreatic… Expand
2015
2015
To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF‐04937319, as add‐on… Expand
2014
2014
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2014
2014
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl… Expand
  • table 1
  • table 2
  • table 3